You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

TASIMELTEON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Tasimelteon, and when can generic versions of Tasimelteon launch?

Tasimelteon is a drug marketed by Apotex, MSN, and Teva Pharms Usa Inc. and is included in three NDAs.

The generic ingredient in TASIMELTEON is tasimelteon. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tasimelteon profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tasimelteon

A generic version of TASIMELTEON was approved as tasimelteon by TEVA PHARMS USA INC on December 12th, 2022.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TASIMELTEON?
  • What are the global sales for TASIMELTEON?
  • What is Average Wholesale Price for TASIMELTEON?
Drug patent expirations by year for TASIMELTEON
Drug Prices for TASIMELTEON

See drug prices for TASIMELTEON

Recent Clinical Trials for TASIMELTEON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Saint-Joseph UniversityPhase 3
Vanda PharmaceuticalsPhase 2
Vanda PharmaceuticalsPhase 4

See all TASIMELTEON clinical trials

Pharmacology for TASIMELTEON
Anatomical Therapeutic Chemical (ATC) Classes for TASIMELTEON
Paragraph IV (Patent) Challenges for TASIMELTEON
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
HETLIOZ LQ Oral Suspension tasimelteon 4 mg/mL 214517 1 2024-04-01
HETLIOZ Capsules tasimelteon 20 mg 205677 3 2018-01-31

US Patents and Regulatory Information for TASIMELTEON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex TASIMELTEON tasimelteon CAPSULE;ORAL 211607-001 Dec 20, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Msn TASIMELTEON tasimelteon CAPSULE;ORAL 211654-001 Jan 12, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa Inc TASIMELTEON tasimelteon CAPSULE;ORAL 211601-001 Dec 12, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for TASIMELTEON

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Vanda Pharmaceuticals Netherlands B.V. Hetlioz tasimelteon EMEA/H/C/003870
Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.,
Authorised no no yes 2015-07-03
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.